Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
J. Clin. Invest. Jehonathan H. Pinthus, et al. 114:1774 doi:10.1172/JCI22284 [Go to this article.]

Figure 8
Pretreatment with cyclophosphamide or irradiation enhances the effect of systemic therapy with erbB2-specific CR–bearing lymphocytes on LuCaP-35 bone lesions. (A and B) SCID mice bearing established intraosseous LuCaP-35 xenografts were preconditioned with TBI (A) or cyclophosphamide (B) 24 hours before i.v. administration of erbB2-specific (triangles) or TNP-specific (circles) CR–bearing lymphocytes or medium (squares) (n = 10 mice per group).